Menopause Treatment: A Doctor's Guide for 2026

What Is Menopause and When Does It Begin?

Menopause is a single point in time: the day that falls 12 months after a woman's last menstrual period. The average age in the United States is 51, though natural menopause anywhere between 45 and 58 years old falls within the normal range. Premature ovarian insufficiency (POI) occurs before age 40 and carries different treatment priorities.

The Three Stages

Perimenopause begins when ovarian hormone production starts to fluctuate, often 4 to 8 years before the final period. Cycles become irregular. Estrogen can spike unpredictably before falling. This stage is when most women first notice hot flashes, sleep disruption, and mood changes.

Menopause itself is that single retrospective date. You cannot confirm it until 12 months have passed.

Postmenopause is every year that follows. Estrogen and progesterone levels stay chronically low, shifting cardiovascular risk, bone density, and vaginal tissue over the long term.

Why Symptoms Happen

The hypothalamus contains neurons called KNDy cells (kisspeptin, neurokinin B, dynorphin) that normally regulate the thermostat-like control of body temperature. Estrogen withdrawal disrupts that circuit. Neurokinin B receptor activity spikes, triggering the abrupt peripheral vasodilation most women experience as a hot flash. This mechanism is exactly why fezolinetant (Veozah), a neurokinin 3 receptor antagonist, works without touching estrogen at all. [1]

Diagnosing Menopause: What Tests Actually Matter

Most women do not need lab work. Menopause is a clinical diagnosis based on age, symptom history, and 12 months of amenorrhea.

When FSH Testing Is Useful

Follicle-stimulating hormone (FSH) above 40 IU/L on two occasions, at least 4 to 6 weeks apart, supports the diagnosis in ambiguous cases. This is most relevant for women under 45 or those using hormonal contraception that masks bleeding patterns. The Endocrine Society notes that a single FSH result is unreliable during perimenopause because levels fluctuate week to week.

Ruling Out Other Causes

Thyroid dysfunction, hyperprolactinemia, and pregnancy can all mimic perimenopause symptoms. A TSH, prolactin level, and urine hCG are reasonable first steps before attributing irregular cycles to ovarian decline in women under 45.

The Full Menu of Menopause Treatments

No single treatment fits every woman. The decision depends on symptom type, severity, personal health history, and preference.

Systemic Hormone Therapy (HT)

Systemic hormone therapy is the most studied and most effective treatment for moderate-to-severe vasomotor symptoms. It also prevents the accelerated bone loss that follows estrogen withdrawal.

Estrogen-only therapy is appropriate after hysterectomy. Options include oral 17-beta estradiol (0.5 to 2 mg daily), transdermal patches (0.025 to 0.1 mg per day), gels, and sprays. Transdermal routes bypass hepatic first-pass metabolism, producing lower triglyceride and clotting-factor effects compared to oral forms. [2]

Combined estrogen-progestogen therapy is required when the uterus is intact. Progestogen protects the endometrium from estrogen-driven hyperplasia. Options include oral micronized progesterone 100 to 200 mg daily (Prometrium), norethindrone acetate, and the levonorgestrel-releasing IUD (Mirena), which delivers progestogen locally.

The 2023 NAMS Position Statement states: "For women aged younger than 60 years or within 10 years of menopause onset who have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss." [3]

The Timing Hypothesis

The Women's Health Initiative (WHI) enrolled women aged 50 to 79, with a mean age of 63. Its initial results, published in JAMA in 2002, reported increased breast cancer and cardiovascular risk, triggering a worldwide drop in HT prescribing. [4] Subsequent re-analysis by age cohort (the "timing hypothesis") showed that women who began HT within 10 years of menopause or before age 60 had lower all-cause mortality and lower coronary heart disease rates compared to placebo. Women who started HT more than 20 years after menopause did not share that benefit. The Kronos Early Estrogen Prevention Study (KEEPS) and the Danish Osteoporosis Prevention Study (DOPS) both support this window of opportunity concept. [5]

Vaginal (Local) Estrogen

Genitourinary syndrome of menopause (GSM) encompasses vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. Low-dose vaginal estrogen (cream, ring, or tablet) delivers estrogen locally with minimal systemic absorption. Vaginal estradiol 10 mcg inserts (Vagifem) and the vaginal ring (Estring, releasing 7.5 mcg per day) are first-line for GSM. [6] The NAMS 2023 statement explicitly notes that vaginal estrogen carries a different and more favorable risk profile than systemic therapy and can be used in most women with a history of hormone-sensitive cancer after discussion with their oncologist.

Non-Hormonal Prescription Options

Fezolinetant (Veozah) 45 mg oral daily received FDA approval in May 2023 specifically for moderate-to-severe vasomotor symptoms. In the SKYLIGHT 1 and SKYLIGHT 2 trials (N = 1,022 combined), fezolinetant reduced mean weekly moderate-to-severe hot flash frequency by 60% from baseline at week 12, versus 40% with placebo (P<0.001). [1] Liver enzyme monitoring is required at baseline, 3 months, and 6 months.

Paroxetine mesylate (Brisdelle) 7.5 mg is the only FDA-approved SSRI for vasomotor symptoms. It reduces hot flash frequency by approximately 33 to 67% versus placebo across clinical trials. [7]

Escitalopram, venlafaxine, and desvenlafaxine are used off-label. Venlafaxine 75 mg daily reduces hot flash frequency by roughly 60% in breast cancer survivors, based on data from an NCI-sponsored trial (N = 191). [8]

Gabapentin 300 mg three times daily reduces hot flash frequency by 45% versus placebo in a randomized trial (N = 59). [9] It may be especially useful when sleep disruption or neuropathic pain coexist.

Oxybutynin 2.5 to 5 mg daily, an anticholinergic primarily used for overactive bladder, reduced hot flash frequency by 73% versus 29% with placebo in the MsFLASH trial (N = 150). [10]

Ospemifene and Prasterone

Two non-systemic-estrogen options address GSM specifically.

Ospemifene (Osphena) 60 mg oral daily is a selective estrogen receptor modulator approved for moderate-to-severe dyspareunia. It is the only oral non-estrogen option for GSM with strong data showing improvement in vaginal maturation index.

Prasterone (Intrarosa) 6.5 mg vaginal insert nightly is a DHEA precursor that converts locally to estrogen and testosterone in vaginal tissue. A 12-week trial (N = 464) showed statistically significant improvement in vaginal dryness and dyspareunia with no detectable increase in serum estrogen. [11]

Bone Health: Prevention and Treatment

Estrogen withdrawal accelerates bone remodeling. Women lose 1 to 3% of bone mineral density per year in the first 5 years after menopause. [12]

Who Needs a DEXA Scan

The USPSTF recommends bone density screening with DEXA for all women 65 and older, and for younger postmenopausal women whose 10-year fracture risk equals or exceeds that of a 65-year-old white woman with no additional risk factors (approximately 9.3% by FRAX). [13]

Treatment Thresholds

A T-score at or below -2.5 at the spine, hip, or femoral neck meets the WHO definition of osteoporosis. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend pharmacotherapy for women with T-score < -2.5 or T-score between -1.0 and -2.5 with a 10-year FRAX hip fracture probability above 3% or major osteoporotic fracture probability above 20%. [14]

Hormone therapy preserves bone density and reduces fracture risk. The WHI showed 34% reduction in hip fractures and 24% reduction in total fractures with combined HT versus placebo. For women who cannot or will not use HT, oral bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly), denosumab (Prolia 60 mg subcutaneous every 6 months), and raloxifene 60 mg daily are established options.

Cardiovascular Risk: What the Evidence Actually Shows

Heart disease is the leading cause of death in postmenopausal women. Estrogen has direct favorable effects on endothelial function, LDL cholesterol, and insulin sensitivity during the perimenopausal window.

The Critical Age Window

Coronary artery calcium (CAC) scoring studies show that women who initiate estrogen therapy before age 60 have lower CAC progression than matched controls. A 2007 study from the WHI hormone trial re-analysis (N = 10,739) found that women aged 50 to 59 using estrogen-only HT had a 0.32 relative risk of myocardial infarction or death compared to placebo (P = 0.008). [15] That figure is not generalizable to women starting HT after age 70.

Oral estrogen raises triglycerides and C-reactive protein through hepatic first-pass effects. Transdermal estradiol avoids this and may be preferable in women with hypertriglyceridemia or prior VTE, though transdermal HT has not been tested in large RCTs for cardiovascular hard endpoints specifically.

Breast Cancer Risk: Putting the Numbers in Context

The breast cancer question is the single most common barrier to HT use.

Absolute Risk Numbers

The WHI found that combined (estrogen plus medroxyprogesterone acetate) HT was associated with 8 additional breast cancer cases per 10,000 women per year after 5 years of use. [4] That is a small absolute increase, comparable to the risk associated with drinking one alcoholic drink per day or being sedentary.

Estrogen-only HT in WHI was actually associated with fewer breast cancer diagnoses: a hazard ratio of 0.77 (95% CI 0.62 to 0.95) over 7 years. [16]

Micronized progesterone and dydrogesterone appear to carry lower breast cancer risk than synthetic progestogens such as medroxyprogesterone acetate (MPA), based on the French E3N cohort (N = 80,377, follow-up 8.1 years). [17]

Practical Takeaway

For women with moderate-to-severe symptoms, the risk-benefit calculation favors HT for most women under 60 with no personal history of breast cancer. The decision changes meaningfully with a personal history of hormone-receptor-positive breast cancer, BRCA1/2 pathogenic variants, or a 5-year absolute risk above 3% by Tyrer-Cuzick. Those women should be co-managed with oncology.

Comparing Treatment Options: Evidence-Graded Summary

| Treatment | Target Symptom | Evidence Grade | Notes | |---|---|---|---| | Systemic estrogen plus progestogen | Vasomotor, bone, mood, sleep | A | First-line for healthy women <60 or within 10 yr of menopause | | Estrogen-only (post-hysterectomy) | Vasomotor, bone, GSM | A | Lower breast cancer signal than combined HT | | Vaginal estrogen / DHEA / ospemifene | GSM | A | Safe in most breast cancer survivors | | Fezolinetant (Veozah) | Vasomotor | A | Only FDA-approved non-hormonal for VMS; requires LFT monitoring | | Paroxetine 7.5 mg | Vasomotor | A | Only FDA-approved SSRI for VMS | | Venlafaxine 37.5-75 mg | Vasomotor | B | Strong off-label evidence especially in cancer survivors | | Gabapentin 300 mg TID | Vasomotor, sleep | B | Useful when sleep disorder coexists | | Oxybutynin 2.5-5 mg | Vasomotor, OAB | B | Anticholinergic caution in older women | | Bisphosphonates | Bone loss | A | Required when T-score < -2.5 | | CBT / mindfulness | Vasomotor perception, mood | B | Reduces bother score; does not reduce hot flash frequency |

Evidence grades: A = at least one well-powered RCT or consistent meta-analysis; B = multiple cohort studies or smaller RCTs.

Who Should Not Use Systemic Hormone Therapy

Absolute contraindications to systemic estrogen include: [3]

• Active, recent, or suspected hormone-receptor-positive breast cancer
• Active or recent venous thromboembolism (DVT or pulmonary embolism)
• Active or recent arterial thromboembolic disease (stroke, MI)
• Unexplained vaginal bleeding
• Active liver disease (transaminases more than three times the upper limit of normal)
• Known or suspected pregnancy

Relative contraindications include hypertriglyceridemia above 400 mg/dL (transdermal estrogen preferred), uncontrolled hypertension, active gallbladder disease, and migraine with aura (oral estrogen increases stroke risk; transdermal may be acceptable).

Monitoring While on Hormone Therapy

A practical monitoring framework used at HealthRX clinics follows a three-stage schedule built around the evidence base:

Baseline (before prescribing): Blood pressure measurement. Fasting lipid panel and fasting glucose. Pelvic exam and up-to-date cervical cytology. Mammogram within the past 12 months (24 months if <50 years old and no risk factors). DEXA scan for women 50 to 60 with risk factors or any woman 60+. TSH and prolactin if cycles are irregular and age is under 45. Document contraindications explicitly in the chart.

3-month follow-up: Symptom reassessment using a validated tool such as the Menopause Rating Scale (MRS) or the Greene Climacteric Scale. Blood pressure recheck. Dose adjustment if symptom relief is incomplete or side effects (breast tenderness, bloating, irregular bleeding) are present. Fezolinetant users need LFT panel at this visit.

Annual review: Repeat fasting lipids and glucose. Blood pressure. Endometrial assessment (transvaginal ultrasound) if unscheduled bleeding occurs. Repeat mammogram per age-based guidelines. Re-evaluate continued indication. If a woman is older than 60 and started HT before 60, the risk-benefit calculation shifts toward a lower dose or discontinuation conversation, but there is no evidence-based age at which HT must be stopped in a woman doing well.

Lifestyle Interventions: What Actually Moves the Needle

Lifestyle changes rarely eliminate moderate-to-severe symptoms, but they do matter at the margins and carry no risk.

Physical Activity

A meta-analysis of 11 RCTs (N = 1,007) published in Menopause in 2018 found that aerobic exercise reduced hot flash severity scores by 28% compared to sedentary controls, though frequency was not consistently reduced. [18] Resistance training 2 to 3 days per week preserves lean mass and bone density, which are both lost faster after menopause.

Cognitive Behavioral Therapy

CBT reduces the "bother score" of hot flashes without reducing their measured frequency. The MENOS 2 trial (N = 96) showed that a 4-session group CBT program reduced problem-rating scores by 50% versus 14% in control subjects at 6 months. [19] This is a meaningful finding: the cognitive response to a hot flash is modifiable even when the underlying physiology is not.

Dietary Patterns

A Mediterranean-style diet rich in phytoestrogens (soy isoflavones, flaxseed lignans) has shown modest reductions in vasomotor symptom frequency in observational studies. The PREDIMED-Plus trial is examining cardiovascular outcomes in this population but has not yet reported menopause-specific symptom data.

Alcohol and caffeine lower the threshold for vasomotor events in observational cohorts. Reducing intake to fewer than 7 alcoholic drinks per week and limiting caffeine before bed are reasonable suggestions.

Special Populations: When the Standard Approach Changes

Premature Ovarian Insufficiency (POI)

Women with POI face a longer duration of estrogen deficiency than women experiencing natural menopause. The European Society of Human Reproduction and Embryology (ESHRE) POI guideline (2024) recommends HT at minimum until the average age of natural menopause (51 years) to protect bone and cardiovascular health, regardless of symptom burden. [20] This is not optional for most women with POI.

Breast Cancer Survivors

Systemic HT is generally avoided in women with a history of hormone-receptor-positive breast cancer. Vaginal estrogen at low doses (10 mcg or less) and prasterone are discussed individually with the oncologist. Non-hormonal vasomotor treatments (fezolinetant, venlafaxine, gabapentin) are first-line systemic options in this group.

Women Who Have Had a Hysterectomy

Estrogen-only therapy is appropriate and avoids progestogen-related side effects entirely. The WHI estrogen-only arm (N = 10,739, conjugated equine estrogen 0.625 mg) did not show increased breast cancer risk and showed a trend toward reduced breast cancer incidence. [16]

Women Aged 60 to 65 Seeking to Start HT for the First Time

Starting systemic HT for the first time more than 10 years after menopause requires careful individual assessment. Cardiovascular risk is higher, the "timing window" is closed, and the benefit-risk ratio is less favorable. Non-hormonal options should be tried first. Vaginal estrogen for GSM remains appropriate at any age.

Frequently Asked Questions